MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

Trial Details

NCT ID

NCT05735717

Phase

PHASE2

Sponsor

Masonic Cancer Center, University of Minnesota

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Fludarabine
Busulfan
Melphalan
Rituximab
Levetiracetam
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells

Locations (sample)

Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

Histological confirmation of hematological malignancies
Acute leukemias
Acute Myeloid Leukemia (AML) and related precursor neoplasms
Favorable risk AML is defined as having one of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →